Coenzyme Q10 for Cardiovascular Disease

Verdict: Weak, narrow evidence; no proven heart-disease benefit

For cardiovascular disease broadly, coenzyme Q10 is not proven to help, and major regulators authorize no heart-health claim. The only credible signal is a possible mortality benefit in patients with chronic heart failure (HFrEF) already on standard medication, where it may serve as an adjunct, never a substitute, for guideline therapy.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The strongest data sit in a narrow group: chronic heart-failure (HFrEF) patients on standard therapy. The Q-SYMBIO European subgroup (PMID 33708164, n=231, 300 mg/day) reported lower major cardiovascular events (HR 0.47), and a pooled meta-analysis found reduced all-cause mortality (PMID 34185874, RR 0.69). But this signal is industry-tied and not robust: the Cochrane review (PMID 33513566) rated the same mortality estimate as uncertain (RR 0.68, CI 0.45-1.03, p=0.07) with low-to-moderate quality evidence.

Outside heart failure the case weakens further. A post-MI/coronary meta-analysis showed no significant reduction in recurrent ischemic events (PMID 35155860, HR 0.82, p=0.18), and the blood-pressure benefit is a small surrogate effect (PMID 34746965, systolic -3.65 mmHg) that does not equate to fewer heart attacks or strokes.

Authorities decline to endorse it. EFSA found no established cause-and-effect for any CoQ10 health claim, the US FDA treats disease claims as unapproved 'new drug' marketing, and Harvard Health states there is no convincing evidence it boosts heart health. Mayo and Cleveland Clinic allow only cautious adjunct use in heart failure. Hence Tier C: real but weak and group-specific, not a primary-prevention therapy.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L5 Clinical bodiesAuthoritative stance
0.48
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.468
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

PMID: 33708164 隨機對照試驗 n = 231
Finding: CoQ10 300 mg/day reduced major adverse cardiovascular events and improved NYHA class versus placebo in the European subgroup; consistent with main Q-SYMBIO trial showing reduced cardiovascular mortality.
⚠️ Industry-funded Effect size: [object Object]
View on PubMed
PMID: 34185874 統合分析 n = 1,573
Finding: Pooled CoQ10 supplementation (100-300 mg/day) was associated with reduced all-cause mortality and improved exercise capacity versus placebo in HFrEF patients on guideline-directed medical therapy.
Academic Effect size: [object Object]
View on PubMed
PMID: 34746965 統合分析 n = 532
Finding: CoQ10 supplementation produced a modest but statistically significant reduction in systolic blood pressure; effect on diastolic BP was smaller and less consistent across trials.
Academic Effect size: [object Object]
View on PubMed
PMID: 33513566 Cochrane SR n = 1,573
Finding: Cochrane review concluded uncertainty remains regarding CoQ10's effect on mortality and hospitalization in heart failure due to heterogeneity and risk of bias; possible reduction in mortality but evidence quality rated low to moderate. Caution warranted before routine clinical adoption.
Academic Effect size: [object Object]
View on PubMed
PMID: 35155860 統合分析 n = 887
Finding: CoQ10 adjunct therapy showed modest reductions in oxidative stress markers and improved endothelial function post-MI, but evidence for hard ischemic event reduction (recurrent MI, stroke) remains insufficient and confidence intervals cross unity.
Mixed funding Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
not generally recognized as safe and effective for the referenced uses and therefore are considered "new drugs" source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established between the consumption of coenzyme Q10 and the claimed effects source↗
L4c UK NHS
Cautious
Advise people with migraine that the food supplement riboflavin (400 mg once a day) may be effective in reducing migraine frequency and intensity for some people. source↗
L4d TW TFDA / 衛福部
Cautious
訂定「食品原料輔酵素Q10 (Coenzyme Q10)之使用限制及標示規定」 source↗
L5b Mayo Clinic
Cautious
CoQ10 may improve congestive heart failure symptoms source↗
L5c Cleveland Clinic
Neutral
CoQ10 may help heart failure symptoms but is not a substitute for standard therapy source↗
L5d Harvard Health
Cautious
there is no convincing evidence that CoQ10 supplements boost heart health source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-coenzyme-q10-001 繁體中文版 →